| 172.39 0.135 (0.08%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 209.81  |
1-year : | 245.06 |
| Resists | First : | 179.63 |
Second : | 209.81 |
| Pivot price | 170.92 |
|||
| Supports | First : | 170.64 |
Second : | 165.08 |
| MAs | MA(5) : | 171.99 |
MA(20) : | 170.43 |
| MA(100) : | 156.47 |
MA(250) : | 140.4 |
|
| MACD | MACD : | 1.3 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 59.8  |
D(3) : | 62.2 |
| RSI | RSI(14): 55.3 |
|||
| 52-week | High : | 179.63 | Low : | 107.43 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IBB ] has closed below upper band by 35.7%. Bollinger Bands are 1.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 174.79 - 175.62 | 175.62 - 176.39 |
| Low: | 170.02 - 170.99 | 170.99 - 171.89 |
| Close: | 170.83 - 172.32 | 172.32 - 173.72 |
The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
Fri, 09 Jan 2026
Here's Why Biotech ETFs Are Rallying Hard - TradingView — Track All Markets
Fri, 26 Dec 2025
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? - Yahoo Finance
Mon, 17 Nov 2025
iShares Biotechnology ETF: The M&A Wave Behind The Suddenly Booming Biotech Sector - Seeking Alpha
Mon, 03 Nov 2025
Why the Tide in Biotech May Finally Be Turning and What iShares Biotechnology ETF (IBB) Signals - The Motley Fool
Sun, 26 Oct 2025
StockWatch: Top 3 Biotech ETFs Finally Bounce Back with the Market - Genetic Engineering and Biotechnology News
Mon, 20 Oct 2025
Biotech ETFs Bounce Back in 2025: Here's Why - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|